Clinical Trial Detail

NCT ID NCT01974765
Title Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

peritoneal carcinoma

ovarian carcinoma

fallopian tube carcinoma

Therapies

Enzalutamide

Age Groups: adult

No variant requirements are available.